Literature DB >> 16920271

The anion channel blocker, 4,4'-dinitrostilbene-2,2'-disulfonic acid prevents neuronal death and excitatory amino acid release during glycolysis inhibition in the hippocampus in vivo.

A Camacho1, T Montiel, L Massieu.   

Abstract

Neuronal death associated with cerebral ischemia and hypoglycemia is related to increased release of excitatory amino acids (EAA) and energy failure. The intrahippocampal administration of the glycolysis inhibitor, iodoacetate (IOA), induces the accumulation of EAA and neuronal death. We have investigated by microdialysis the role of exocytosis, glutamate transporters and volume-sensitive organic anion channel (VSOAC) on IOA-induced EAA release. Results show that the early component of EAA release is inhibited by riluzole, a voltage-dependent sodium channel blocker, and by the VSOAC blocker, tamoxifen, while the early and late components are blocked by the glutamate transport inhibitors, L-trans-pyrrolidine 2,4-dicarboxylate (PDC) and DL-threo-beta-benzyloxyaspartate (DL-TBOA); and by the VSOAC blocker 4,4'-dinitrostilbene-2,2'-disulfonic acid (DNDS). Riluzole, DL-TBOA and tamoxifen did not prevent IOA-induced neuronal death, while PDC and DNDS did. The VSOAC blockers 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB) and phloretin had no effect either on EAA efflux or neuronal damage. Results suggest that acute inhibition of glycolytic metabolism promotes the accumulation of EAA by exocytosis, impairment or reverse action of glutamate transporters and activation of a DNDS-sensitive mechanism. The latest is substantially involved in the triggering of neuronal death. To our knowledge, this is the first study to show protection of neuronal death by DNDS in an in vivo model of neuronal damage, associated with deficient energy metabolism and EAA release, two conditions involved in some pathological states such as ischemia and hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920271     DOI: 10.1016/j.neuroscience.2006.07.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice.

Authors:  Ana María Estrada-Sánchez; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2010-04-18       Impact factor: 3.996

Review 2.  Functional importance of the astrocytic glycogen-shunt and glycolysis for maintenance of an intact intra/extracellular glutamate gradient.

Authors:  Arne Schousboe; Helle M Sickmann; Anne B Walls; Lasse K Bak; Helle S Waagepetersen
Journal:  Neurotox Res       Date:  2010-03-20       Impact factor: 3.911

Review 3.  Glycolytic metabolism supports microglia training during age-related neurodegeneration.

Authors:  Alberto Camacho-Morales
Journal:  Pharmacol Rep       Date:  2022-04-03       Impact factor: 3.919

4.  Contribution of NMDA and non-NMDA receptors to in vivo glutamate-induced calpain activation in the rat striatum. Relation to neuronal damage.

Authors:  Perla Del Río; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2008-02-13       Impact factor: 3.996

5.  Cerebellar granule neurons are more vulnerable to transient transport-mediated glutamate release than to glutamate uptake blockade. correlation with excitatory amino acids levels.

Authors:  Ana María Estrada-Sánchez; Alberto Camacho; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2007-03       Impact factor: 4.414

6.  Maternal cafeteria diet exposure primes depression-like behavior in the offspring evoking lower brain volume related to changes in synaptic terminals and gliosis.

Authors:  Luis A Trujillo-Villarreal; Viktor J Romero-Díaz; Iván Alberto Marino-Martínez; Lizeth Fuentes-Mera; Marco Antonio Ponce-Camacho; Gabriel A Devenyi; M Mallar Chakravarty; Alberto Camacho-Morales; Eduardo E Garza-Villarreal
Journal:  Transl Psychiatry       Date:  2021-01-14       Impact factor: 6.222

7.  Neural ablation of the PARK10 candidate Plpp3 leads to dopaminergic transmission deficits without neurodegeneration.

Authors:  Sandra Gómez-López; Ana Valeria Martínez-Silva; Teresa Montiel; Daniel Osorio-Gómez; Federico Bermúdez-Rattoni; Lourdes Massieu; Diana Escalante-Alcalde
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.